



Contact: Julie Bryant  
VP Business Development and Marketing  
GeneGo, Inc.  
(858) 756 7996  
julie@genego.com

## Chenomx and GeneGo Offer Metabolomics Data Integration

Manchester, United Kingdom (June 11, 2007)

Chenomx, Inc., a leading provider of software and compound libraries for NMR-based metabolomics, and GeneGo, Inc., a worldwide leader in data analysis solutions for systems biology and pathway analysis, are pleased to announce a partnership to provide metabolomics data integration between their software products.

This partnership combines Chenomx's powerful and easy-to-use metabolomics software, Chenomx NMR Suite, with GeneGo's MetaCore and MetaDrug Discovery platform, providing researchers with the ability to perform sophisticated pathway analysis and visualization.

"Chenomx's partnership with GeneGo offers several significant advantages to our shared customers," explains Jack Newton, Director of Product Development for Chenomx. "First, our customers will now be able to combine Chenomx NMR Suite's powerful metabolite identification and quantification capabilities with GeneGo's pathway analysis tools, thereby improving their interpretation and understanding of the underlying biology. This integration also allows our customers to integrate genomic and proteomic data sources with their Chenomx metabolomics data."

"We initiated this partnership based on customer requests for seamless functional analysis of their NMR and mass spec metabolomics data," said Julie Bryant VP of business development. "Metabolic data is hugely important in diagnostics and drug discovery, as any major disease fundamentally affects core biochemical pathways. Yet, MetaCore/MetaDrug is the only product in the field which enables direct parsing, pathway and network analysis of human metabolic data and its integration with genomics, proteomics and genetic data. Now, our customers will have this functionality accessed directly from Chenomx software".

### ***About Chenomx, Inc.***

Chenomx, Inc. is a privately-held Canadian company that specializes in the development of complex mixture analysis software for broad application in life science technologies. With world-class expertise in NMR spectroscopy, pharmaceutical sciences, and computer software, Chenomx offers a broad range of software products and compound databases to support the metabolomics communities' research efforts. Chenomx's flagship product, Chenomx NMR Suite, provides a rich set of tools for identifying and quantifying metabolites in complex NMR Spectra. More information on Chenomx and its solutions is available at [www.chenomx.com](http://www.chenomx.com).

***About GeneGo, Inc.***

GeneGo, Inc. develops systems biology technology such as compound based [pathway analysis](#), cheminformatics & [bioinformatics software](#) for life science research. The original computational MetaDiscovery™ platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, [proteomics](#), metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 4.3™, assists pharmaceutical scientists in the areas of target selection and validation, [data mining](#) in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 2.0™ is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase™ represents the knowledge base for MetaCore.

For more information, please visit the company's web site at [www.genego.com](http://www.genego.com)

**MetaCore™, MetaBase™, MetaDrug™, MetaLink™, MetaDiscovery™, MetaTox™ and MetaMiner™, 1-2-3 Workflow™ are trademarks of GeneGo, Inc.**